Randomized, double-blind Phase 2b clinical trial (EXACT-2) of XC001 (encoberminogene rezmadenovec), in refractory angina
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Encoberminogene rezmadenovec (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms EXACT-2
- 13 Jan 2025 New trial record
- 07 Jan 2025 According to a XyloCor Therapeutics media release, company plans to dose the first patient in the Phase 2 study by year end 2025.
- 07 Jan 2025 According to a XyloCor Therapeutics media release, company plans to initiate this study in 2025.